Irene Moreno Candilejo

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors

Malaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo et al. · European Journal of Cancer · 2017 · 75 citations

Lymphoid Neoplasia, Medicine, Malignant Blood Disorder +8

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Christina Guo, Maxime Chénard-Poirier, Desamparados Roda et al. · The Lancet Oncology · 2020 · 68 citations

Hematological Malignancy, Medicine, Pharmacology +10

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

Angelika Terbuch, Crescens Tiu, Irene Moreno Candilejo et al. · Clinical Cancer Research · 2020 · 20 citations

181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)

Peter Schmid, Sherene Loi, Luis de la Cruz‐Merino et al. · ESMO Open · 2024 · 18 citations · Full text

Breast Oncology, Immunology, Pathology +20

660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)

Cesar A. Perez, Jason T. Henry, Nehal J. Lakhani et al. · Annals of Oncology · 2023 · 16 citations · Full text

Tumoral Pathology, Malignant Disease, Medicine +9